MAP2K7 and cancer: Similar to MEK inhibitors, the specific RTK driving KRASG12C inhibitor resistance is cell type specific, so that while individual RTK inhibitors might be effective in blocking KRASG12C-inhibitor resistance in a specific cancer cell line, broad inhibition of RTK signaling will be required to delay therapeutic resistance and make KRASG12C inhibitors clinically efficacious [18,125,126,127].